Through comprehensive multi-cohort screening, we discovered that UBE2N acts as an oncogenic driver, accelerating disease progression, remodeling the tumor immune microenvironment, and conferring resistance to both immunotherapy and chemotherapy in LUAD. Here, UBE2N is linked to neoplasm.